Amyloid. 2009;16(3):178-80. doi: 10.1080/13506120903090940.
We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.
我们报告了一例伴有淋巴浆细胞性白血病的淀粉样变性 A 型病例，自开始采用环磷酰胺利妥昔单抗方案抑制致病γ重链以来，该患者肾病综合征已稳定 17 个月。血清游离轻链和外周血 CD20 阳性细胞是该患者有用的血液学标志物。利妥昔单抗可能是伴有 B 细胞淋巴增生性疾病的淀粉样变性 A 型的有效治疗选择。
